Financial Performance - The company's operating revenue for Q1 2022 was CNY 266,736,074.86, representing a 12.48% increase compared to CNY 237,149,805.31 in the same period last year[6] - Net profit attributable to shareholders for Q1 2022 was CNY 135,277,246.77, a 34.60% increase from CNY 100,499,516.16 in the previous year[6] - Basic earnings per share for Q1 2022 were CNY 1.5087, down 35.10% from CNY 1.6750 in the previous year[6] - The company reported a net profit margin improvement, with net profit increasing due to higher revenue and controlled costs[39] - The net profit for the current period is 135,277,246.77, compared to 100,499,516.16 in the previous period, representing an increase of approximately 34.6%[42] - The total profit for the current period is 156,134,338.16, up from 118,963,858.22 in the previous period, indicating a growth of about 31.2%[42] Cash Flow - The net cash flow from operating activities was negative CNY 111,805,582.88, a decline of 76.02% compared to negative CNY 63,517,522.38 in the same period last year[6] - Cash flow from operating activities generated a net outflow of -111,805,582.88, compared to -63,517,522.38 in the previous period, reflecting a worsening cash flow situation[47] - Total cash inflow from operating activities increased by 40.98% to 174,143,515.60 CNY, attributed to higher sales collections[15] - Total cash outflow from operating activities rose by 52.88% to 285,949,098.48 CNY, driven by increased material reserves and payments[15] - The net cash flow from investing activities decreased by 57.70% to -171,578,869.93 CNY, due to increased payments for projects and equipment[15] - The cash flow from investing activities resulted in a net outflow of -171,578,869.93, compared to -108,803,254.71 in the previous period, indicating increased investment expenditures[52] - The net cash flow from financing activities was 34,874,462.61 CNY, reflecting an increase in bank loans and stock repurchases[18] - The company raised 40,000,000.00 in cash from financing activities, with a net cash inflow of 34,874,462.61 from financing activities overall[52] Assets and Liabilities - Total assets at the end of Q1 2022 were CNY 3,102,413,394.89, an increase of 2.80% from CNY 3,018,041,385.96 at the end of the previous year[6] - Current assets totaled CNY 1,981,125,743.65, up from CNY 1,942,586,927.29, indicating an increase of 1.99%[30] - The total liabilities decreased to CNY 298,164,404.81 from CNY 347,740,657.31, a reduction of 14.2%[36] - Shareholders' equity attributable to the parent company was CNY 2,804,248,990.08, up 5.02% from CNY 2,670,300,728.65 at the end of the previous year[6] - Shareholders' equity rose to CNY 2,804,248,990.08, compared to CNY 2,670,300,728.65, indicating an increase of 5.0%[39] Inventory and Accounts Payable - Inventory increased by 36.47% to CNY 143,963,001.95, attributed to an increase in finished goods and material stock[14] - The company reported a significant increase in accounts payable by 227.21% to CNY 19,823,539.43, due to increased purchases of raw materials[14] Research and Development - Research and development expenses rose to CNY 21,011,414.14, up from CNY 16,753,131.31, marking a significant increase of 25.5%[39] Shareholder Information - The total number of common shareholders at the end of the reporting period was 18,720[19] - The largest shareholder, Aokang Group Co., Ltd., holds 16.08% of shares, with 14,470,312 shares pledged[19]

Financial Performance - The company's revenue for Q3 2021 was ¥228,247,551.98, a decrease of 38.33% compared to the same period last year[6] - Net profit attributable to shareholders for Q3 2021 was ¥331,191,245.13, an increase of 105.74% year-on-year[6] - The net profit excluding non-recurring gains and losses for Q3 2021 was ¥99,931,522.95, down 37.74% compared to the same period last year[6] - Basic earnings per share for Q3 2021 were ¥3.6799, reflecting a 105.74% increase year-on-year[6] - The company’s net profit for the first nine months of 2021 was ¥583,360,526.57, a 69.75% increase compared to the same period in 2020[14] - Net profit for the quarter was CNY 583,360,526.57, up from CNY 343,664,826.66, indicating a year-over-year increase of about 69.8%[66] - The company reported a total comprehensive income of CNY 583,360,526.57, reflecting the same amount as the net profit attributable to the parent company[70] Assets and Liabilities - Total assets as of the end of Q3 2021 reached ¥2,635,367,840.90, a 22.71% increase from the end of the previous year[6] - Total assets increased to CNY 2,635,367,840.90 from CNY 2,147,678,235.61, representing a growth of approximately 22.7%[32] - Total liabilities decreased to CNY 159,129,264.40 from CNY 173,243,939.20, a reduction of approximately 8.1%[41] - Total liabilities reached approximately $173.24 million, with non-current liabilities at $2.92 million[86] Shareholder Information - Shareholders' equity attributable to the parent company was ¥2,476,238,576.50, up 25.42% from the end of the previous year[6] - The total number of ordinary shareholders at the end of the reporting period was 21,763[18] - The largest shareholder, Pingtan Yingke Shengdao Venture Capital Partnership, holds 18.82% of the shares, totaling 16,940,220 shares[18] - The company has a total of 16,940,220 shares held by Pingtan Yingke Shengdao, which are subject to lock-up restrictions until June 16, 2023[21] Cash Flow - The company's cash flow from operating activities showed a significant decline, with a net amount of ¥12,111,036.04, down 95.75% year-on-year[6] - The net cash flow from operating activities decreased by 95.75% to ¥12,111,036.04 compared to ¥284,841,410.60 in the same period last year[17] - Cash inflow from operating activities totaled CNY 558,736,126.98, a decrease from CNY 706,833,372.12 in the previous period[73] - Cash outflow from operating activities was CNY 546,625,090.94, compared to CNY 421,991,961.52 in the previous period, indicating increased operational expenses[73] - The company’s total cash inflow from financing activities was CNY -996,550,000.00, indicating a significant outflow related to financing[76] Investments and R&D - The net cash flow from investing activities improved by 38.73%, amounting to -¥255,135,892.16, compared to -¥416,435,639.42 in the previous year[17] - Research and development expenses rose to CNY 45,771,510.81 from CNY 37,367,940.71, reflecting an increase of about 22.5%[66] - Future outlook includes continued investment in R&D and potential market expansion strategies to enhance growth[66] Inventory and Receivables - The company reported an increase in accounts receivable by 75.54% to ¥619,117,355.72 as of September 30, 2021[14] - Inventory increased by 57.20% to ¥78,466,399.41, attributed to expanded production capacity[14] - Accounts receivable increased significantly to ¥619,117,355.72 from ¥352,683,146.05 year-on-year[26] - The company reported a significant increase in prepayments to ¥76,384,675.64 from ¥28,809,934.07 year-on-year[26] Financial Adjustments and Standards - The company adjusted its financial statements in accordance with new leasing standards, impacting the balance sheet[79] - The company has not made any adjustments related to the new leasing standards for prior comparative data[91] - The third quarter report was not audited, indicating a potential area for further scrutiny[91]

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2021, representing a year-on-year increase of 25%[21]. - The net profit attributable to shareholders was RMB 300 million, up 30% compared to the same period last year[21]. - The company achieved operating revenue of ¥560,409,533.94, representing a year-on-year increase of 23.19%[39]. - Net profit attributable to shareholders reached ¥252,169,281.44, up 38.03% compared to the same period last year[39]. - The company reported a negative net cash flow from operating activities of ¥19,216,945.19, a decline of 114.01% compared to the previous year[39]. - The company’s basic and diluted earnings per share were both ¥2.8019, an increase of 3.52% year-on-year[39]. - The company’s production costs increased by 64.43% to ¥43.60 million, primarily due to higher sales volumes and increased distribution costs[55]. - The total cash and cash equivalents decreased by 122.08% to -¥233,985,637.34, driven by reduced cash flows from investing and financing activities[60]. - The revenue from the rabies vaccine (human diploid cells) was ¥548,837,621.42, with a gross margin of 92.48%[60]. Research and Development - The company is investing RMB 200 million in R&D for new vaccine technologies, focusing on mRNA vaccine development[21]. - The company invested ¥34,430,500 in R&D, marking a 67.41% increase year-on-year[39]. - The company has established multiple vaccine R&D platforms and actively collaborates with universities and research institutions to enhance its R&D capabilities[44]. - The company’s R&D efforts are guided by innovation, with a focus on both independent and collaborative projects[44]. - The company has 10 ongoing R&D projects, including the six-valent norovirus vaccine and the ACYW135 meningococcal conjugate vaccine, with various stages of development expected to progress into clinical trials[50]. - The company’s R&D capabilities are supported by a robust team and various vaccine platforms, including recombinant protein and inactivated vaccine platforms[54]. Market Strategy and Expansion - The company plans to expand its vaccine production capacity by 40% in response to increasing market demand[21]. - Future guidance estimates a revenue growth of 20% for the second half of 2021, driven by new product launches[21]. - The company has entered into a strategic partnership with a leading biotech firm to enhance its market presence in Southeast Asia[21]. - The company is actively exploring acquisition opportunities to strengthen its product portfolio and market reach[21]. - The company employs a direct sales model for its non-immunization program vaccines, with provincial-level bidding for product access[45]. - The company has a strategy focused on "product upgrades" and "filling domestic gaps" in vaccine development, balancing research risks through innovation and collaboration[93]. Regulatory and Compliance - The management highlighted potential risks related to regulatory changes and supply chain disruptions that could impact operations[21]. - The company has implemented a series of regulatory measures to enhance vaccine distribution channels and strengthen oversight, including the Vaccine Administration Law effective from December 1, 2019[50]. - The company emphasizes the importance of quality control and has established a product quality control system and adverse reaction handling system in compliance with relevant laws and regulations[93]. - The company has established a comprehensive quality management system to ensure product quality throughout the entire lifecycle, from development to market feedback[54]. - The company has implemented various environmental management systems, including wastewater treatment and laboratory waste management, which are effectively executed[121]. Environmental and Social Responsibility - The company has a wastewater treatment station with a daily processing capacity of 200 tons, and it has installed online monitoring equipment for chemical oxygen demand, total phosphorus, and ammonia nitrogen, sampling four times daily without exceeding pollution factor limits[113]. - The company reported a total discharge of 4.032 tons for chemical oxygen demand, 0.504 tons for ammonia nitrogen, and 0.0252 tons for total phosphorus, all within the permissible limits[112]. - The company has established a comprehensive environmental emergency response plan, updated in April 2021, and has completed the necessary filings with local environmental authorities[114]. - The company has received environmental impact assessment approvals for multiple projects, including the vaccine production expansion project approved in March 2021[114]. - The company conducts annual monitoring of pollutant emissions through a third-party environmental testing agency, with results meeting the standards set by GB21907-2008[121]. Shareholder and Corporate Governance - The company held its annual general meeting on May 10, 2021, with an investor participation rate of 63.49%[101]. - The company plans to grant up to 100,000 restricted stocks under the 2021 restricted stock incentive plan, representing 0.1667% of the total share capital of 60 million shares[107]. - The total number of shares increased from 60 million to 90 million following a capital increase plan approved on May 10, 2021, distributing RMB 15 per 10 shares and converting capital reserves into shares[160]. - The company has a commitment from certain shareholders not to seek control of the company for three years post-listing[173]. - The company has not implemented any share buyback programs during the reporting period[164]. Financial Position and Assets - The total assets at the end of the reporting period were ¥2,329,132,618.10, an increase of 8.45% from the previous year[39]. - The company reported a total current assets of approximately ¥1.79 billion as of June 30, 2021, compared to ¥1.78 billion at the end of 2020, reflecting a slight increase of 0.83%[197]. - Cash and cash equivalents decreased to approximately ¥911.51 million from ¥1.15 billion, representing a decline of about 20.39%[197]. - Accounts receivable increased significantly to approximately ¥616.53 million, up from ¥352.68 million, marking an increase of approximately 74.83%[197]. - The company’s non-current assets totaled approximately ¥543.16 million, up from ¥368.17 million, indicating a growth of about 47.5%[200].

Financial Performance - Chengdu Kanghua Biological Products Co., Ltd. reported a revenue of RMB 300 million for the first half of 2021, representing a year-on-year increase of 25%[21]. - The company achieved operating revenue of ¥560,409,533.94, representing a year-on-year increase of 23.19%[29]. - The net profit attributable to shareholders reached ¥252,169,281.44, up 38.03% compared to the previous year[29]. - The net profit after deducting non-recurring gains and losses was ¥243,478,859.84, reflecting a 33.58% increase year-on-year[29]. - Future performance guidance suggests a revenue growth target of 30% for the full year 2021[21]. - Revenue from the freeze-dried rabies vaccine reached ¥548,837,621.42, a 24.75% increase year-over-year, with a gross margin of 92.48%[61]. - The total profit increased, leading to an income tax expense of ¥46,052,119.71, a 37.46% increase compared to the previous period[59]. Research and Development - Research and development expenses for the first half of 2021 reached RMB 50 million, accounting for 16.67% of total revenue[21]. - Research and development expenses amounted to ¥34,430,500, marking a significant increase of 67.41%[39]. - The company has established multiple vaccine research platforms and actively collaborates with universities and research institutions to enhance its R&D capabilities[45]. - The company has 10 ongoing R&D projects, including the six-valent norovirus vaccine and the ACYW135 meningococcal conjugate vaccine, with several projects expected to enter clinical trials in 2021-2022[50]. - The company is focused on product innovation and new technology development to mitigate research and development risks[93]. Market Expansion and Strategy - The company plans to expand its market presence by increasing production capacity for its rabies vaccine, targeting a production volume of 5 million doses annually by the end of 2022[21]. - The company aims to launch a new meningococcal polysaccharide vaccine by the end of 2021, which is expected to capture a significant market share[21]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[21]. - The company has been actively increasing its R&D investment and attracting talent in production and research to drive operational efficiency[47]. Assets and Financial Position - The total assets of the company as of June 30, 2021, amounted to RMB 1.5 billion, an increase of 15% compared to the end of 2020[21]. - The total assets at the end of the reporting period were ¥2,329,132,618.10, an increase of 8.45% from the previous year[29]. - Cash and cash equivalents at the end of the period were ¥911,505,783.19, a 14.21% decrease due to increased payments for investments and vaccine expansion[64]. - Accounts receivable increased to ¥616,534,027.50, reflecting a 10.05% rise due to higher sales revenue[64]. Risk Management - The management highlighted potential risks including regulatory changes and market competition, and outlined strategies to mitigate these risks[6]. - The company faces risks related to industry policy changes, particularly with new regulations enhancing vaccine quality and distribution requirements[93]. - The company is committed to improving its product quality control systems and adverse reaction handling processes in compliance with relevant laws[93]. Environmental and Compliance - The company has implemented a complete environmental management system, including various management regulations and pollution treatment facilities, meeting the discharge standards set by environmental laws[121]. - The company has not faced any administrative penalties due to environmental issues during the reporting period[117]. - The company updated its environmental emergency response plan in April 2021, which includes risk assessment and resource investigation reports[114]. Shareholder and Capital Structure - The company did not distribute cash dividends or bonus shares during the reporting period[6]. - The company approved a profit distribution plan for 2020, distributing RMB 15.00 per 10 shares and increasing capital stock by 30,000,000 shares, raising total shares to 90,000,000[164]. - The company has a total of 90,000,000 shares post-capital increase, representing 100% of the total share capital[164]. - The company’s shareholder structure includes significant holdings from domestic legal entities and natural persons, with 48.37% and 26.63% respectively[164]. Operational Efficiency - The company has established a comprehensive quality management system to ensure product quality throughout the entire lifecycle, from application to market feedback[54]. - The company has implemented low-nitrogen combustion technology in its production boilers to reduce emissions[113]. - The company has a comprehensive management mechanism and emergency plan for handling vaccination adverse reactions, regularly submitting reports to regulatory authorities[119].

Financial Performance - The company's operating revenue for 2020 was CNY 1,038,636,032.50, representing an increase of 87.26% compared to CNY 554,636,645.87 in 2019 [26]. - The net profit attributable to shareholders for 2020 was CNY 408,046,268.44, a significant increase of 118.57% from CNY 186,686,665.96 in 2019 [26]. - The net profit after deducting non-recurring gains and losses was CNY 402,958,968.71, up 119.45% from CNY 183,618,256.41 in 2019 [26]. - The basic earnings per share for 2020 was CNY 7.77, an increase of 87.23% compared to CNY 4.15 in 2019 [26]. - The total assets at the end of 2020 were CNY 2,147,678,235.61, reflecting a growth of 211.65% from CNY 689,136,081.99 at the end of 2019 [26]. - The net assets attributable to shareholders at the end of 2020 were CNY 1,974,434,296.41, an increase of 243.59% from CNY 574,650,243.31 at the end of 2019 [26]. - The company reported a net cash flow from operating activities of CNY 369,564,379.69, which is a 102.25% increase from CNY 182,729,747.72 in 2019 [26]. - The total revenue for the year 2020 reached CNY 1,038,636,032.50, representing a 87.26% increase compared to CNY 554,636,645.87 in 2019 [65]. - The net profit attributable to the parent company was 408.05 million CNY, with a year-on-year increase of 118.57% [57]. - The company achieved a gross margin of 93.95% in the bioproducts sector, with a slight decrease of 0.22% from the previous year [68]. Dividend Policy - The company plans to distribute a cash dividend of 15 RMB per 10 shares to all shareholders, based on a total of 60,000,000 shares, and will also increase capital by 5 shares for every 10 shares held [7]. - The total cash dividend amount is 90 million CNY, which represents 22.06% of the net profit attributable to ordinary shareholders in the consolidated financial statements for 2020 [135]. - The company has not distributed cash dividends in the years 2018 and 2019, with the 2020 dividend being the first since its public offering [132]. - The cash dividend distribution plan complies with the company's articles of association and dividend management measures [131]. - The total distributable profit for the year is 647,054,507.10 CNY, with the cash dividend accounting for 100% of the profit distribution [131]. Research and Development - The company invested 58.25 million CNY in R&D, marking a 155.66% increase compared to the previous year [57]. - The company launched 10 R&D projects, with several vaccines expected to enter clinical trials in 2021-2022 [60]. - The company has established multiple vaccine research and development platforms and has participated in national projects such as the 863 Program [42]. - The R&D personnel count increased to 53 in 2020, up from 30 in 2019, indicating a focus on enhancing research capabilities [79]. - The company is actively pursuing partnerships for R&D projects with institutions like the Chinese Academy of Sciences and universities [57]. Product and Market Development - The company's core product, the freeze-dried human rabies vaccine (human diploid cells), contributed over 90% of profits during the reporting period [46]. - The rabies vaccine accounted for 96.27% of total revenue, generating CNY 999,942,062.54 in 2020, up from CNY 537,721,664.49 in 2019 [65]. - The company is positioned to benefit from the growing vaccine market in emerging countries, driven by increasing public awareness and supportive policies [47]. - The company expanded its marketing coverage to 1,667 disease control centers and 3,400 vaccination points [57]. - The company is advancing the construction of a second workshop for viral vaccines with an annual capacity of 2 million doses for the freeze-dried human rabies vaccine [57]. Risk Management - The company emphasizes the importance of risk management in new product development, which typically requires 5-10 years for clinical research and regulatory approvals, indicating a high level of uncertainty in achieving expected outcomes [6]. - The company is closely monitoring changes in industry regulations, particularly those related to vaccine production and sales, to mitigate operational risks associated with policy shifts [6]. - The company faces risks from industry policy changes, requiring compliance with new regulations such as the Vaccine Administration Law and Drug Administration Law, which enhance industry standards and oversight [120]. - The company has established a product quality control system and adverse reaction handling system to mitigate risks associated with adverse vaccine reactions, ensuring compliance with relevant laws [120]. Shareholding and Governance - The company has committed to not transferring or managing its shares for 36 months following the public offering, with a lock-up period extending for an additional 2 years under certain conditions [136]. - The company has established a two-year period post-lock-up during which any share reduction must adhere to the issuance price [141]. - The company has implemented strict guidelines for share transfers by its executives to maintain market confidence [141]. - The company has committed to ensuring the stability of control by its actual controller and will not seek to gain control over the company through its shareholding [166]. - The company has made commitments to protect the legitimate rights and interests of minority investors, ensuring transparency and accountability in its operations [166]. Compliance and Legal Matters - The company reported no significant litigation or arbitration matters during the year [174]. - There were no penalties or rectification situations reported during the period [175]. - The company has not engaged in any related party transactions during the reporting period [177][178][180]. - The company has not faced any delisting situations following the annual report disclosure [172]. - The company has not reported any significant accounting policy changes or major accounting error corrections during the reporting period [169].

成都康华生物制品股份有限公司 2021 年第一季度报告 成都康华生物制品股份有限公司 2021 年第一季度报告 公告编号：2021-022 2021 年 4 月 1 成都康华生物制品股份有限公司 2021 年第一季度报告 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季度报告的董事会会议。 公司负责人王清瀚、主管会计工作负责人唐名太及会计机构负责人(会计 主管人员)吴文年声明：保证季度报告中财务报表的真实、准确、完整。 2 成都康华生物制品股份有限公司 2021 年第一季度报告 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|-----------------------------------------|----------|-------------- ...

成都康华生物制品股份有限公司 2020 年第三季度报告全文 成都康华生物制品股份有限公司 2020 年第三季度报告 2020-047 2020 年 10 月 1 成都康华生物制品股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人王清瀚、主管会计工作负责人唐名太及会计机构负责人(会计主 管人员)吴文年声明：保证季度报告中财务报表的真实、准确、完整。 2 成都康华生物制品股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |-----------------------------------------------------------------------------------|-------------------------|----- ...

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 454,913,998.32, representing a 67.97% increase compared to CNY 270,838,551.93 in the same period last year[27]. - The net profit attributable to shareholders of the listed company reached CNY 182,691,172.79, a significant increase of 115.51% from CNY 84,771,951.56 in the previous year[27]. - The net profit after deducting non-recurring gains and losses was CNY 182,265,864.96, up 116.57% from CNY 84,160,105.95 year-on-year[27]. - The net cash flow from operating activities was CNY 137,148,544.77, reflecting a 140.66% increase compared to CNY 56,989,684.74 in the same period last year[27]. - The basic earnings per share were CNY 4.0598, which is a 115.51% increase from CNY 1.8838 in the previous year[27]. - The total assets at the end of the reporting period amounted to CNY 1,892,548,466.21, a 174.63% increase from CNY 689,136,081.99 at the end of the previous year[27]. - The net assets attributable to shareholders of the listed company were CNY 1,744,647,142.37, showing a 203.60% increase from CNY 574,650,243.31 at the end of the previous year[27]. - The weighted average return on net assets was 27.43%, an increase of 6.76% compared to 20.67% in the previous year[27]. Research and Development - The company has eight major ongoing research projects, including the "human rabies vaccine (human diploid cells) immobilized bioreactor culture process"[37]. - The company has established a research platform for viral vaccines, bacterial vaccines, and genetic engineering, focusing on continuous optimization of existing production processes[45]. - The company is advancing multiple research projects, including the rabies vaccine and tetanus vaccine, with clinical trials expected to commence in 2020-2021[51]. - The company is conducting experimental research on the immune efficacy of existing vaccine products to enhance safety and production processes[86]. - Research and development expenses increased by 226.39% to ¥20,566,974.67 from ¥6,301,410.88 in the previous year, indicating a significant investment in new product development[58]. Market and Sales - The core product, freeze-dried human rabies vaccine (human diploid cells), has seen increased sales due to market demand during the pandemic[37]. - The total sales volume of the ACYW135 meningococcal polysaccharide vaccine was 372,010,000 doses in the first half of 2020, a 79.43% increase from 207,320,000 doses in the first half of 2019[54]. - The sales volume of rabies vaccine reached 3,733,880,000 doses in the first half of 2020, a 70.47% increase from 2,190,410,000 doses in the same period last year[54]. - The marketing network has expanded to cover 1,504 disease control centers, enhancing brand recognition through public education initiatives[50]. Financial Position - The company reported a net increase in cash and cash equivalents of ¥1,059,778,693.33, a 2,661.17% increase compared to ¥38,381,570.39 in the previous year[58]. - The proportion of cash and cash equivalents to total assets rose to 68.77% from 24.11%, attributed to the successful fundraising from the initial public offering[62]. - The company's total liabilities decreased by 2.49% as short-term borrowings were fully repaid during the reporting period[62]. - The total current assets reached ¥1,722,540,581.88, up from ¥577,305,456.74, indicating an increase of approximately 198.5%[163]. - The total non-current liabilities amounted to ¥1,698,245.31, compared to ¥1,418,960.47 in the previous period, indicating an increase of approximately 19.6%[178]. Corporate Governance and Compliance - The company has disclosed potential risks and corresponding countermeasures in its report, which investors should pay attention to[6]. - The company has established a product quality control system and adverse reaction handling system to mitigate risks associated with vaccine quality and adverse events[83]. - The company has not utilized any of the raised funds during the reporting period, with a net amount of raised funds totaling ¥98,097.30[67]. - There were no significant litigation or arbitration matters during the reporting period[96]. - The company has no major related party transactions during the reporting period[99]. Shareholder Information - The company issued 15 million shares at a price of 70.37 RMB per share, raising a total of 1.05555 billion RMB[122]. - After the issuance, the total share capital of the company increased to 60 million shares[125]. - The largest shareholder, Pingtan Yingke Shengdao Investment Partnership, holds 20.60% of the shares, totaling 12,359,880 shares[126]. - The second largest shareholder, Aokang Group Co., Ltd., holds 16.08% of the shares, totaling 9,646,875 shares[126]. - The company has a total of 29,665 common stock shareholders at the end of the reporting period[126]. Future Outlook - The company is actively expanding its vaccine product line, with two new vaccines in preclinical research stages, including a diphtheria genetic engineering vaccine and a rotavirus genetic engineering vaccine[54]. - The company follows a research and development strategy focused on "product upgrades" and "filling domestic gaps," continuously innovating products and processes[86]. - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[91].